Cargando…
Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy
Cancer immunotherapy has already shown significant improvements by combining different antibodies specific for distinct immune checkpoints, such as Ipilimumab and Nivolumab. Here, we tested combinatorial treatments of immunomodulatory antibodies, previously generated in our laboratory, for their eff...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998846/ https://www.ncbi.nlm.nih.gov/pubmed/35408827 http://dx.doi.org/10.3390/ijms23073466 |
_version_ | 1784685040651730944 |
---|---|
author | Passariello, Margherita Yoshioka, Asami Takahashi, Kota Hashimoto, Shu-ichi Rapuano Lembo, Rosa Manna, Lorenzo Nakamura, Koji De Lorenzo, Claudia |
author_facet | Passariello, Margherita Yoshioka, Asami Takahashi, Kota Hashimoto, Shu-ichi Rapuano Lembo, Rosa Manna, Lorenzo Nakamura, Koji De Lorenzo, Claudia |
author_sort | Passariello, Margherita |
collection | PubMed |
description | Cancer immunotherapy has already shown significant improvements by combining different antibodies specific for distinct immune checkpoints, such as Ipilimumab and Nivolumab. Here, we tested combinatorial treatments of immunomodulatory antibodies, previously generated in our laboratory, for their effects on hPBMC activation, either upon stimulation with SEB or in co-cultures with tumor cells by cytokine secretion assays. We found that some of them showed additive or synergistic effects, and on the basis of these observations, we constructed, for the first time, four novel bispecific tribodies (TR), made up of a Fab derived from one anti-IC mAb and two scFvs derived from another mAb targeting a different IC. All four TRs cotargeting either programmed cell death protein 1 (PD-1) and Lymphocyte Activating 3 (LAG-3) or programmed death-ligand 1 (PD-L1) and LAG-3 retained binding affinity for their targets and the antagonistic effects of their parental mAbs, but some of them also showed an increased ability to induce lymphocyte activation and increased in vitro cytotoxicity against tumor cells compared to parental antibodies used either alone or in combinatorial treatments. Furthermore, none of the tribodies showed significant increased cytotoxicity on human cardiomyocytes. Considering that the tribody format reduces production costs (as only one construct provides the inhibitory effects of two antibodies), has an intermediate molecular size (100 kDa) which is well suited for both tumor penetration and an acceptable half-life, we think that these novel immunomodulatory TRBs have the potential to become precious tools for therapeutic applications, particularly in monotherapy-resistant cancer patients. |
format | Online Article Text |
id | pubmed-8998846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89988462022-04-12 Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy Passariello, Margherita Yoshioka, Asami Takahashi, Kota Hashimoto, Shu-ichi Rapuano Lembo, Rosa Manna, Lorenzo Nakamura, Koji De Lorenzo, Claudia Int J Mol Sci Article Cancer immunotherapy has already shown significant improvements by combining different antibodies specific for distinct immune checkpoints, such as Ipilimumab and Nivolumab. Here, we tested combinatorial treatments of immunomodulatory antibodies, previously generated in our laboratory, for their effects on hPBMC activation, either upon stimulation with SEB or in co-cultures with tumor cells by cytokine secretion assays. We found that some of them showed additive or synergistic effects, and on the basis of these observations, we constructed, for the first time, four novel bispecific tribodies (TR), made up of a Fab derived from one anti-IC mAb and two scFvs derived from another mAb targeting a different IC. All four TRs cotargeting either programmed cell death protein 1 (PD-1) and Lymphocyte Activating 3 (LAG-3) or programmed death-ligand 1 (PD-L1) and LAG-3 retained binding affinity for their targets and the antagonistic effects of their parental mAbs, but some of them also showed an increased ability to induce lymphocyte activation and increased in vitro cytotoxicity against tumor cells compared to parental antibodies used either alone or in combinatorial treatments. Furthermore, none of the tribodies showed significant increased cytotoxicity on human cardiomyocytes. Considering that the tribody format reduces production costs (as only one construct provides the inhibitory effects of two antibodies), has an intermediate molecular size (100 kDa) which is well suited for both tumor penetration and an acceptable half-life, we think that these novel immunomodulatory TRBs have the potential to become precious tools for therapeutic applications, particularly in monotherapy-resistant cancer patients. MDPI 2022-03-23 /pmc/articles/PMC8998846/ /pubmed/35408827 http://dx.doi.org/10.3390/ijms23073466 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Passariello, Margherita Yoshioka, Asami Takahashi, Kota Hashimoto, Shu-ichi Rapuano Lembo, Rosa Manna, Lorenzo Nakamura, Koji De Lorenzo, Claudia Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title_full | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title_fullStr | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title_full_unstemmed | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title_short | Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy |
title_sort | novel bi-specific immuno-modulatory tribodies potentiate t cell activation and increase anti-tumor efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998846/ https://www.ncbi.nlm.nih.gov/pubmed/35408827 http://dx.doi.org/10.3390/ijms23073466 |
work_keys_str_mv | AT passariellomargherita novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT yoshiokaasami novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT takahashikota novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT hashimotoshuichi novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT rapuanolemborosa novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT mannalorenzo novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT nakamurakoji novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy AT delorenzoclaudia novelbispecificimmunomodulatorytribodiespotentiatetcellactivationandincreaseantitumorefficacy |